National Institutes of Health Clinical Center

Who's at Risk for Heart Attacks? Not Just Who You Might Think!

Retrieved on: 
Tuesday, March 15, 2022
Online, Health, Center, Depression, Risk, Interpersonal relationship, Education, The Chicago School of Professional Psychology, American Heart Association, Smoke, Centers for Disease Control and Prevention, GLOBE, Divorce, Work, TCS, Clinical professor, Korea Disease Control and Prevention Agency, Diet, McQueen, Exercise, Food, COVID-19, Fear, Student, Infarction, Friends, Mental, Sleep, Smoking, Mental health, Topical steroid withdrawal, Chicago school, Family, National Institute, National Institutes of Health Clinical Center, Hypertension, Aggarwal, Mayo Clinic, Research, Cardiac arrest, Heart, Psychology, Nursing, Diabetes, Myocardial infarction, Pharmaceutical industry, Medical device, Dietary supplement, Meat, Medicine, Dan Wikler, Lancet

The study also found that psychological stress was even more impactful to heart health than diabetes, hypertension, diet, and exercise (Yusuf et al., 2004).

Key Points: 
  • The study also found that psychological stress was even more impactful to heart health than diabetes, hypertension, diet, and exercise (Yusuf et al., 2004).
  • These stressors can create risk for heart attacks even in people who appear to be coping fine.
  • Its time we re-examine who is at risk for cardiac arrest and do something pre-emptively to minimize chances of a heart attack.
  • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Monday, February 28, 2022
GLOBE, Massachusetts General Hospital, Board of directors, National Institutes of Health Clinical Center, Eli, Board, Eli Lilly, Hospital, University, Drug development, Cytokine, Center, DFCI, Berkeley, Biomarker, Dana–Farber Cancer Institute, Biotechnology, Drug, Autoimmune disease, Cancer, Lung cancer, SAN, Patient, Technology, Immunotherapy, Large-cell lung carcinoma, CEO, Research, Pharmaceutical industry, New York University

SAN DIEGO and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Leena Gandhi, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • SAN DIEGO and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Leena Gandhi, M.D., Ph.D., to its Board of Directors.
  • She is a renowned immuno-oncologist and widely recognized as a clinical investigator for her track record of bringing important medical breakthroughs to patients, said Fredrik Wiklund, President and CEO of Bright Peak Therapeutics.
  • Her clinical insights and development experience will be highly valuable to Bright Peak as we continue to advance our emerging product portfolio.
  • Bright Peak is pioneering a novel technology to chemically synthesize and conjugate enhanced cytokines to a diverse array of molecules, such as monoclonal antibodies, creating a novel class of Bright Peak Immunocytokines.

aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Risk, National Center for Advancing Translational Sciences, Head, Rare Disease Day, ATyr Pharma, NIH, Sarcoidosis, Awareness, Annual report, COVID-19, National, Clinical trial, Organization, Biology, Private Securities Litigation Reform Act, Interstitial lung disease, RNA transfection, Q&A, LIFE, National Institutes of Health Clinical Center, SAN, EST, Forward-looking statement, Patient, PST, Goal, Rare disease, Research, SEC, Pharmaceutical industry

For more information and to register, please visit the Rare Disease Day at NIH page on the NIHs website.

Key Points: 
  • For more information and to register, please visit the Rare Disease Day at NIH page on the NIHs website.
  • Rare Disease Day takes place worldwide, typically on the last day of February, to raise awareness among policymakers and the public about rare diseases and their impact on patients lives.
  • aTyr is developing its lead therapeutic candidate, efzofitimod, for patients with severe inflammatory lung diseases with high unmet medical need.
  • Pulmonary sarcoidosis is a rare disease that affects close to 200,000 people in the United States and has limited treatment options.

Xoran Reaches 1000 Installations Worldwide

Retrieved on: 
Friday, February 18, 2022
XCAT, Patient, Ear, Cone beam computed tomography, TM, AI, CEO, CT scan, SBIR, Health, PACS, Anesthesia, National Cancer Institute, National, Temporal bone, Degenerative disease, OR, National Heart, Lung, and Blood Institute, Brain, ANN, Innovation, Neurosurgery, National Institutes of Health Clinical Center, NCI, Otorhinolaryngology, Federal Food, Drug, and Cosmetic Act, Robotics, FDA, Dermatology, Allergy, Critical Care Medicine (journal), Sale, CT, Tomography, NHLBI, 3D, NIH, 3D CT, Human skull symbolism, Nose, Research, University, Internet access, Ophthalmology, National Institute, Lung, Medical imaging, Medical device

ANN ARBOR, Mich., Feb. 18, 2022 /PRNewswire/ -- "Fast on the heels of Xoran's announcement of 900 MiniCAT™ and 50 VetCAT™ installations, we are proud to announce that Xoran has reached 1,000 system installations worldwide," says Misha Rakic, CEO of Xoran Technologies.

Key Points: 
  • ANN ARBOR, Mich., Feb. 18, 2022 /PRNewswire/ --"Fast on the heels of Xoran's announcement of 900 MiniCAT and 50 VetCAT installations, we are proud to announce that Xoran has reached 1,000 system installations worldwide," says Misha Rakic, CEO of Xoran Technologies.
  • As the pioneer and medical market leader in point-of-care cone beam CT since 2001, Xoran's team of domestic sales and customer service, along with international distributors, reaches 1,000 global device installs.
  • Xoran specifically designed its xCAT suite of products for use in the operating room and critical care unit.
  • With this progression, Xoran is working to demonstrate the potential of integrating surgical navigation capability into a mobile CT device.

Amptify and CounselEAR Empower Hearing Clinics with Systems Integration

Retrieved on: 
Thursday, January 20, 2022
ASHA, Patient, Technology, Research, NIH, Speech, ADA, Audiology, Topical steroid withdrawal, COO, Hearing, Weather, Patient satisfaction, National Institute, History, Quality of life, Washington University in St. Louis, Noise, Communication, Doctor of Audiology, National Institutes of Health Clinical Center, AAA, Hearing loss, Partnership, University, Dentistry, Pharmaceutical industry, Medicine

In an era of perpetual change within the field of hearing health, the Amptify CounselEAR partnership arms clinicians with the tools and technology they need to compete, differentiate, and thrive.

Key Points: 
  • In an era of perpetual change within the field of hearing health, the Amptify CounselEAR partnership arms clinicians with the tools and technology they need to compete, differentiate, and thrive.
  • Available immediately, clinics that use CounselEAR can trigger patient invitations to the Amptify DTx and outsource patient aural rehabilitation to Amptify's world-class specialists.
  • "By utilizing this integration and the Amptify Provider Portal, clinics can improve patient satisfaction, increase new hearing aid use time, save money on patient initiated visits, and efficiently achieve ASHA, ADA, and AAA best practice aural rehabilitation recommendations", said Brian Urban, AuD, President of CounselEAR.
  • Recognizing the importance of ongoing counseling and aural rehabilitation to optimize patient outcomes, CounselEAR is excited to partner with Amptify to offer clinics an exceptional tool to help patients live their best lives.

Spaulding Rehabilitation Hospital at Harvard Medical School and Highland Instruments, Inc., Jointly Announce National Institutes of Health Funded Clinical Trial Investigating Highland's Electrosonic Stimulation Technology to Treat Postural Instability in

Retrieved on: 
Tuesday, December 7, 2021
Harvard Medical School, U.S. News & World Report, Lists of diseases, Spaulding Rehabilitation Hospital, Unified Parkinson's disease rating scale, Postural drainage, Patient, Principal investigator, Rehabilitation, Technology, Mortality, Low back pain, National, PT, Phase, Quality of life, SBIR, Clinical trial, Physical therapy, National Institutes of Health Clinical Center, NIH, MD, Social Security, Parkinson's disease, Disability, Department, Gait, Observation, MIT, Physical medicine and rehabilitation, Doctor of Philosophy, News, RCT, PD, Mass, MMSc, MPH, Master of Education, Pharmaceutical industry, Hospital

BOSTON, Dec. 7, 2021 /PRNewswire/ --Spaulding Rehabilitation Hospital at Harvard Medical School and Highland Instruments, Inc., ("Highland") today jointly announced the launch of a National Institutes of Health ("NIH") funded Clinical Trial investigating Highland Instruments' Electrosonic Stimulation ("ESStim"), a novel noninvasive brain stimulation technology, to treat Postural Instability in Parkinson's Disease ("PD")1.

Key Points: 
  • BOSTON, Dec. 7, 2021 /PRNewswire/ --Spaulding Rehabilitation Hospital at Harvard Medical School and Highland Instruments, Inc., ("Highland") today jointly announced the launch of a National Institutes of Health ("NIH") funded Clinical Trial investigating Highland Instruments' Electrosonic Stimulation ("ESStim"), a novel noninvasive brain stimulation technology, to treat Postural Instability in Parkinson's Disease ("PD")1.
  • Patients' Quality-of-Life ("QOL") self-assessments also significantly improved, with notable improvements in functional mobility, activities of daily living, and emotional domains.
  • Highland Instruments is a privately held medical device company, founded in 2007 by researchers trained at Harvard Medical School and MIT.
  • It is the official teaching hospital for Harvard Medical School's Department of Physical Medicine and Rehabilitation and the main campus of the Spaulding Rehabilitation Network.

Dean of University of Phoenix College of Nursing is Named Finalist in The Greater Phoenix Chamber’s ATHENA Awards

Retrieved on: 
Wednesday, October 27, 2021
Women, Nursing, General Health, Health, Continuing, University, Consumer, Education, Woman, JW Marriott Hotels, Mentorship, University, College, Greater Phoenix Chamber of Commerce, ATHENA, University of Phoenix, Leadership, Careers New Zealand, Student, RN, National Institute, Nursing, National Institutes of Health Clinical Center, Education, Medicine

The Greater Phoenix Chamber announced the 11 women chosen as finalists for its prestigious ATHENA Awards, continuing its strong tradition of recognizing outstanding Valley businesswomen.

Key Points: 
  • The Greater Phoenix Chamber announced the 11 women chosen as finalists for its prestigious ATHENA Awards, continuing its strong tradition of recognizing outstanding Valley businesswomen.
  • Kathleen Winston is an exceptional leader, and we are fortunate to have her at our university.
  • Dr. Winston has extensive experience in the nursing industry as a clinician, educator, and academic Dean.
  • The Greater Phoenix Chambers ATHENA Awards program recognizes and celebrates the achievements of businesswomen across the Greater Phoenix region.

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

Retrieved on: 
Wednesday, October 13, 2021
People, Facioscapulohumeral muscular dystrophy, Form 10-Q, Professor, Program, Terminology, Duchenne muscular dystrophy, Private Securities Litigation Reform Act, Nasdaq, LinkedIn, IND, Myopathy, DMD, Intention, FSHD, Congress, Security (finance), Adult, MAD, DM1, SEC, MPH, Therapy, Neurology, IPO, Disease, Degenerative disease, Neuromuscular disease, Patient, Clinical trial, Development, Pediatrics, GLOBE, Science, Research, Securities and Exchange Commission (Philippines), R, Company, University, National Institutes of Health Clinical Center, Review, Twitter, Safety, DYN, Doctor of Philosophy, 23rd Street station (IND Eighth Avenue Line), Clinical, Associate, COVID-19, Pharmaceutical industry

WALTHAM, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, hosts its first Research and Development Day today focused on the Company’s co-lead development programs for rare muscle diseases, Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). “The Muscle to Move to the Clinic” live virtual event (8:00-10:30 a.m. ET) as well as the replay and slide presentation are available at https://investors.dyne-tx.com/events/event-details/dyne-rd-day.

Key Points: 
  • For its DMD program, Dyne intends to initiate a global, placebo-controlled, multiple-ascending dose (MAD) clinical trial to evaluate DYNE-251 in patients with mutations amenable to exon 51 skipping.
  • The Company also intends to initiate a global, placebo-controlled, MAD clinical trial evaluating DYNE-101 in adult patients with DM1.
  • Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.
  • However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Incyte Names New Member to Its Board of Directors

Retrieved on: 
Tuesday, September 28, 2021
Biotechnology, Pharmaceutical, Health, Emory University, Annual report, Solution, Therapy, Bloomberg Distinguished Professorships, Security (finance), Board of directors, National, U.S. Securities and Exchange Commission, Patient, Board, Senior, Grady Memorial Hospital, Marketing, Assistant director, Epidemiology, Company, Oncology, Leadership, Medicine, Johns Hopkins University, Biotechnology, National Institutes of Health Clinical Center, Science, American Cancer Society, Johns Hopkins, Research, Walter Reed National Military Medical Center, Internal medicine, National Cancer Institute, Management, Pharmaceutical industry

Incyte (Nasdaq:INCY) announces the appointment of Otis Brawley, M.D., as a new member of its Board of Directors, effective September 27, 2021.

Key Points: 
  • Incyte (Nasdaq:INCY) announces the appointment of Otis Brawley, M.D., as a new member of its Board of Directors, effective September 27, 2021.
  • We are very pleased to welcome Otis to the Incyte Board of Directors.
  • As part of the Incyte Board, I join a very experienced and diverse team dedicated to scientific discovery and to the development of new, innovative medicines for patients.
  • Dr. Brawley is also a member of the boards of directors of Lyell Immunopharma, Inc. and PDS Biotechnology Corporation.

Virtual Reality and Robotics Team Up to Heal

Retrieved on: 
Tuesday, September 21, 2021
Goal, Lucid, Partnership, Chronic pain, PCP, Efficiency, School, Walking, Patient, Injury, Virtual reality, Lists of diseases, National Institutes of Health Clinical Center, KAMX, Neuro, CEO, Rehabilitation, Face, LLC, Brain, MX, National Institute, UTMB, Research, FTF, Hip, Learning, Robotics, DRIVE, Knee pain, Moody, DeBakey High School for Health Professions, Human, Education, Medical device

Brown is a leader in collaborating with engineering professionals to research and develop products for the advancement of patient rehabilitation," says Mike Christian.

Key Points: 
  • Brown is a leader in collaborating with engineering professionals to research and develop products for the advancement of patient rehabilitation," says Mike Christian.
  • Patients complete physical therapy goals and exercises while being cognitively engaged in a virtual world.
  • In the recent article, "Virtual Reality and Robotics Team Up to Heal" , Mike Christian states, "The future combined powers of VR and robotics has the potential to profoundly change the face of physical and neuro rehabilitation."
  • From the Future is a leader in developing highly engaging and interactive virtual reality software.